BioCryst Pharmaceuticals has commenced a Phase I trial evaluating BCX4161 in healthy volunteers for the treatment of hereditary angioedema (HAE).
The study, being conducted at Quotient Clinical in the UK, is designed to assess the safety, pharmacokinetics and pharmacodynamics of BCX4161, a novel selective inhibitor of plasma kallikrein.
Go deeper with GlobalData
BioCryst president and chief executive officer Jon Stonehouse said the daily, oral administration of a safe and effective prophylactic drug would revolutionise treatment for HAE patients.
"BCX4161 has the potential to be the first oral treatment developed specifically for the prevention of HAE attacks," Stonehouse said.
BioCryst BCX4161 previously demonstrated potent and selective inhibition of plasma kallikrein and an encouraging safety profile in nonclinical safety studies and in-vitro and in-vivo studies.
The objectives of Phase I trial are to measure safety, characterise plasma drug levels and estimate the level of kallikrein inhibition achieved subsequent to oral dosing of BCX4161.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe results of the study are anticipated in 2013.
If the objectives of the study are met, a Phase II programme in HAE patients is expected to be undertaken.
